Inhibition of phosphoinositide 3-kinase potentiates relaxation of porcine coronary arteries induced by nitroglycerin by decreasing phosphodiesterase type 5 activity

Circulation Journal

Volumn 76, Issue 1, 2012, Pages 230-237

  Dou, Dou ^a,b   Guo, Yixuan ^a,b   Ying, Lei ^a   Liu, Juan ^a   Xu, Xiaojian ^a   Yu, Xiaoxing ^a   Gao, Yuansheng ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Nitric oxide; Smooth muscle; Vasodilatation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 8 BROMO CYCLIC GMP; CYCLIC GMP; GLYCERYL TRINITRATE; ISOPRENALINE; MILRINONE; NIFEDIPINE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE V; ZAPRINAST;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; CORONARY ARTERY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; NONHUMAN; SWINE; VASOCONSTRICTION; VASODILATATION; WESTERN BLOTTING;

ANIMALS; CHROMONES; CORONARY VESSELS; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ENZYME INHIBITORS; MILRINONE; MODELS, ANIMAL; MORPHOLINES; NIFEDIPINE; NITROGLYCERIN; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PURINONES; SIGNAL TRANSDUCTION; SWINE; VASODILATION; VASODILATOR AGENTS;

EID: 84255172400     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0802     Document Type: Article

References (49)

1. Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 2009; 34: 115-127.
2. Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc Res 2009; 82: 261-271.
3. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004; 37: 449-471.
4. Sata M, Nagai R. Phosphatidylinositol 3-kinase: A key regulator of vascular tone? Circ Res 2002; 91: 273-275.
5. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Aktdependent phosphorylation. Nature 1999; 399: 601-605.
6. Hosoya M, Ohashi J, Sawada A, Takaki A, Shimokawa H. Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice. Circ J 2010; 74: 798-806.
7. Viard P, Exner T, Maier U, Mironneau J, Nürnberg B, Macrez N. Gbetagamma dimers stimulate vascular L-type Ca2+ channels via phosphoinositide 3-kinase. FASEB J 1999; 13: 685-694.
8. Viard P, Macrez N, Mironneau C, Mironneau J. Involvement of both G protein alphas and beta gamma subunits in beta-adrenergic stimulation of vascular L-type Ca2+ channels. Br J Pharmacol 2001; 132: 669-676.
9. Quignard JF, Mironneau J, Carricaburu V, Fournier B, Babich A, Nurnberg B, et al. Phosphoinositide 3-kinase gamma mediates angiotensin II-induced stimulation of L-type calcium channels in vascular myocytes. J Biol Chem 2001; 276: 32545-32551.
10. Le Blanc C, Mironneau C, Barbot C, Henaff M, Bondeva T, Wetzker R, et al. Regulation of vascular L-type Ca2+ channels by phosphatidylinositol 3,4,5-trisphosphate. Circ Res 2004; 95: 300-307.
11. Macrez N, Mironneau C, Carricaburu V, Quignard JF, Babich A, Czupalla C, et al. Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca2+ channels. Circ Res 2001; 89: 692-699.
12. Miao L, Dai Y, Zhang J. Mechanism of RhoA/Rho kinase activation in endothelin-1-induced contraction in rabbit basilar artery. Am J Physiol Heart Circ Physiol 2002; 283: H983-H989.
13. Wehrwein EA, Northcott CA, Loberg RD, Watts SW. Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension. J Pharmacol Exp Ther 2004; 309: 1011-1019.
14. Seok YM, Azam MA, Okamoto Y, Sato A, Yoshioka K, Maeda M, et al. Enhanced Ca2+-dependent activation of phosphoinositide 3-kinase class IIα isoform-Rho axis in blood vessels of spontaneously hypertensive rats. Hypertension 2010; 56: 934-941.
15. Han SJ, Vaccari S, Nedachi T, Andersen CB, Kovacina KS, Roth RA, et al. Protein kinase B/Akt phosphorylation of PDE3A and its role in mammalian oocyte maturation. EMBO J 2006; 25: 5716-5725.
16. Ahmad F, Lindh R, Tang Y, Weston M, Degerman E, Manganiello VC. Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB. Biochem J 2007; 404: 257-268.
17. Qin X, Zheng X, Qi H, Dou D, Raj JU, Gao Y. cGMP-dependent protein kinase in regulation of basal tone and in nitroglycerin- and nitric oxide-induced relaxation in porcine coronary artery. Eur J Physiol (Pflugers Arch) 2007; 454: 913-923.
18. Qi H, Zheng X, Qin X, Dou D, Xu H, Raj JU, et al. PKG regulates the basal tension and plays a major role in nitrovasodilator-induced relaxation of porcine coronary veins. Br J Pharmocol 2007; 152: 1060-1069.
19. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003; 93: 280-291.
20. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007; 100: 309-327.
21. Kass DA, Takimoto E, Nagayama T, Champion HC. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res 2007; 75: 303-314.
22. Corbin JD, Turko IV, Beasley A, Francis SH. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 2000; 267: 2760-2767.
23. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 2002; 277: 3310-3317.
24. Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000; 57: 976-983.
25. Turko IV, Francis SH, Corbin JD. Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem 1998; 273: 6460-6466.
26. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 1996; 50: 1-5.
27. Dou D, Zheng X, Qin X, Qi H, Liu L, Raj JU, et al. Role of cGMPdependent protein kinase in development of tolerance to nitroglycerine in porcine coronary arteries. Br J Pharmacol 2008; 153: 497-507.
28. Dou D, Ma H, Zheng X, Ying L, Guo Y, Yu X, et al. Degradation of leucine zipper-positive isoform of MYPT1 may contribute to development of nitrate tolerance. Cardiovasc Res 2010; 86: 151-159.
29. Gao Y, Dhanakoti S, Trevino EM, Sander FC, Portugal AM, Raj JU. Effect of oxygen on cyclic GMP-dependent protein kinase-mediated relaxation in ovine fetal pulmonary arteries and veins. Am J Physiol 2003; 285: L611-L618.
30. Kollau A, Hofer A, Russwurm M, Koesling D, Keung WM, Schmidt K, et al. Contribution of aldehyde dehydrogenase to mitochondrial bioactivation of nitroglycerin: Evidence for the activation of purified soluble guanylate cyclase through direct formation of nitric oxide. Biochem J 2005; 385(Pt 3): 769-777.
31. Yuan R, Sumi M, Benet LZ. Investigation of aortic CYP3A bioactivation of nitroglycerin in vivo. J Pharmacol Exp Ther 1997; 281: 1499-1505.
32. Nakahira A, Minamiyama Y, Takemura S, Hirai H, Sasaki Y, Okada S, et al. Coadministration of carvedilol attenuates nitrate tolerance by preventing cytochrome p450 depletion. Circ J 2010; 74: 1711-1717.
33. Ignarro LJ, Kadowitz PJ. The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Annu Rev Pharmacol Toxicol 1985; 25: 171-191.
34. Warner TD, Mitchell JA, Sheng H, Murad F. Effects of cyclic GMP on smooth muscle relaxation. Adv Pharmacol 1994; 26: 171-194.
35. Ignarro LJ. Haem-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: A unique transduction mechanism for transcellular signaling. Pharmacol Toxicol 1990; 67: 1-7.
36. Chinkers M, Garbers DL, Chang MS, Lowe DG, Chin HM, Goeddel DV, et al. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989; 338: 78-83.
37. Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 2003; 93: 96-105.
38. Lincoln TM, Cornwell TL. Intracelluar cyclic GMP receptor proteins. FASEB J 1993; 7: 328-338.
39. Fayard E, Xue G, Parcellier A, Bozulic L, Hemmings BA. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curr Top Microbiol Immunol 2010; 346: 31-56.
40. Scheid MP, Woodgett JR. PKB/AKT: Functional insights from genetic models. Nat Rev Mol Cell Biol 2001; 2: 760-768.
41. Eisenreich A, Malz R, Pepke W, Ayral Y, Poller W, Schultheiss HP, et al. Role of the phosphatidylinositol 3-kinase/protein kinase B pathway in regulating alternative splicing of tissue factor mRNA in human endothelial cells. Circ J 2009; 73: 1746-1752.
42. Marte BM, Downward J. PKB/Akt: Connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 1997; 22: 355-358.
43. Zhang X, Gan L, Pan H, Guo S, He X, Olson ST, et al. Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem 2002; 277: 45276-45284.
44. Turko IV, Francis SH, Corbin JD. Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. Clin Exp Biochem J 1998; 329 (Pt 3): 505-510.
45. Northcott CA, Hayflick JS, Watts SW. PI3-kinase upregulation and involvement in spontaneous tone in arteries from DOCA-salt rats:Is p110delta the culprit? Hypertension 2004; 43: 885-890.
46. Northcott CA, Hayflick J, Watts SW. Upregulated function of phosphatidylinositol- 3-kinase in genetically hypertensive rats:A moderator of arterial hypercontractility. Clin Exp Pharmacol Physiol 2005; 32: 851-858.
47. Northcott CA, Poy MN, Najjar SM, Watts SW. Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of deoxycorticosterone acetate-salt hypertensive rats. Circ Res 2002; 91: 360-369.
48. Vecchione C, Patrucco E, Marino G, Barberis L, Poulet R, Aretini A, et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma. J Exp Med 2005; 201: 1217-1228.
49. Kobayashi T, Matsumoto T, Kamata K. The PI3-K/Akt pathway:Roles related to alterations in vasomotor responses in diabetic models. J Smooth Muscle Res 2005; 41: 283-302.